Essential requirements for autologous cellular therapies

Edward Samuel, EVP Technical Operations at Achilles Therapeutics, explains why industrialised manufacturing and scale-up of autologous cellular immunotherapies will require fully closed systems and process automation.

AUTOLOGOUS CELL and gene therapies are one of the most exciting tools of modern medicine and have fuelled unprecedented growth in a nascent industry that now has over 2,500 ongoing clinical trials. As the cell and gene therapy field matures, focus is shifting to the development of industrialised manufacturing processes that are capable of reducing vein-to-vein times and delivering large volumes of products in a reliable, reproducible and cost-effective manner. This has become paramount in ensuring that patients have access to these therapies and that reimbursement costs are acceptable to healthcare providers and payers.